<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31774">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01897818</url>
  </required_header>
  <id_info>
    <org_study_id>12-PP-16</org_study_id>
    <nct_id>NCT01897818</nct_id>
  </id_info>
  <brief_title>Communication by Brain - Computer Interface in Amyotrophic Lateral Sclerosis:Feasibility Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      ALS is a severe progressive neurodegenerative disease characterized by degeneration motor
      neurons leading to death in 3 to 5 years. Gradually in time, the patient deprived of all
      motor skills as well as the possibility of communication written and oral developing a state
      close Locked In Syndrome (LIS). The main objective is to establish the feasibility of
      brain-computer interface using the pathological condition, with dependent disabled subjects
      as a means of communication.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>the full achievement of &quot;copy spelling&quot; and &quot;free spelling&quot; tests session 1</measure>
    <time_frame>14 days after inclusion</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>the full achievement of &quot;copy spelling&quot; and &quot;free spelling&quot; tests session 2</measure>
    <time_frame>28 days after inclusion</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>ALS patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>communication system P300 Speller</intervention_name>
    <arm_group_label>ALS patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt;= 18

          -  have a diagnosis of ALS suspected, possible, probable with EMG

          -  be able to follow the study process and to comply with the schedule of visits upon
             entry into the study

          -  understand the purpose of the study

          -  expressing P300 wave in the conditions of the study

        Exclusion Criteria:

          -  have a mental illness or clinical dementia defined clinically significant may hinder
             the patient's ability to follow the procedures of the study

          -  have a significant history of photosensitive epilepsy

          -  have a history of allergy to the gel used for the electrodes

          -  Major protected by law (guardianship, curators)

          -  have uncorrectable visual disorders

          -  not being able to maintain a sitting position and focus on a computer screen for more
             than 30 min.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Claude DESNUELLE, Pr</last_name>
    <email>desnuelle.c@chu-nice.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital de l'Archet I</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claude DESNUELLE, Pr</last_name>
      <email>desnuelle.c@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Claude DESNUELLE, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>July 9, 2013</lastchanged_date>
  <firstreceived_date>July 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
